About Careers MedBlog Contact us

Rheumatoid Arthritis Treatment Widens With the Launch of New Products

by Julia Samuel on January 14, 2015 at 5:07 PM
Font : A-A+

Rheumatoid Arthritis Treatment Widens With the Launch of New Products

GlobalData, a research and consulting firm, reported that the global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023.

GlobalData believes that the market expansion for RA treatment over the coming decade will be driven by increased RA prevalence, as well as the anticipated launches of novel drugs.


The products include three interleukin-6 inhibitors, four biologics novel to the RA market, four Janus kinase (JAK) inhibitors, and numerous biosimilars.

Heather Leach, Ph.D., GlobalData's Analyst covering Immunology, said, "Drugs with novel mechanisms of action, including biologics and small molecules, are welcome additions to the RA therapeutics market. However, this arena will become increasingly crowded over the next decade."

RA is an attractive therapy area for pharmaceutical companies as it is dominated by expensive biologics, and oral JAK inhibitors entering the market are expected to be priced only at a slight discount.

Perhaps the most anticipated event in the RA space is the addition of biosimilars, which are assumed to be priced at a 30% discount to the reference product.

Leach added that while the launch of biosimilars will provide a less expensive therapy option for patients, their lack of regulatory guidelines would delay their availability in a number of regions.

The company's latest report states that US boasts the largest RA treatment space, with a 67% share in 2013 among the 10 major pharmaceutical markets (the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China, and India).

Source: Medindia


Recommended Reading

Latest Drug News

Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
Myeloma Drug: New Findings
In myeloma (blood cancer) cells, cancer-promoting potential of the fatty acid binding proteins was found to determine to be a valid target for myeloma therapeutics
Lower Dose of Acetaminophen Linked to Reduced Serious Liver Injury
Acute liver failure cases dropped after the Food and Drug Administration rule to lower the dosage of acetaminophen
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Rheumatoid Arthritis Treatment Widens With the Launch of New Products Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests